Strides partners with SUDA Pharma in US
Strides Pharma’s wholly-owned subsidiary, Strides Pharma Global Pte Limited, Singapore signed a partnership agreement with SUDA Pharmaceuticals Limited for the exclusive product development, licensing and supply of sumatriptan in the US market.
The mint-flavoured oral spray of sumatriptan is used for the treatment of acute migraine headaches in adults. By means of in-house development and partnerships, the company is positioned to build a portfolio of limited competition products such as sumatriptan, offering exclusivity for a sustainable duration. Sumatriptan (SUD-001H) will utilize SUDA’s recently developed proprietary OroMist hydrotrope technology which enhances the rate and quantity of drug absorption. Thus, it is fast-acting and effective.
The terms of the partnership agreement are such that SUDA will receive an upfront cash payment of US$ 0.4 million in exchange for product development services funded by Strides. SUDA will also work collectively with the Strides team to obtain USFDA approval for the product. In due course, SUDA will be entitled to receive further payment of US$ 0.6 million upon accomplishing certain milestones such as the pilot first-in-man clinical study as well as the submission and approval of the product in the US. Once the drug is on the market, SUDA will receive royalties and a handling fee. An important clause of the agreement grants Strides the right of first refusal for additional territories like the European Union, Australia, New Zealand, Canada, South Africa and Japan.
Strides is a Bangalore headquartered pharmaceutical company operating in the business verticals of Regulated Markets and Emerging Markets. While SUDA Pharmaceuticals Ltd. is a drug delivery company headquartered in Perth, Western Australia.
On Friday, the shares of Strides Pharma opened at a price of Rs. 433.90 per share, and hit a high and low of Rs. 464.40 per share and Rs. 429.95 per share, respectively. At 11:10 am, the stock was trading at Rs. 464.00 per share, up 8.20 per cent.